Literature DB >> 26220041

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

S Jeromin1, A Kohlmann1, M Meggendorfer1, S Schindela1, K Perglerová2, N Nadarajah1, W Kern1, C Haferlach1, T Haferlach1, S Schnittger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26220041     DOI： 10.1038/leu.2015.207

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

2.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

3.  Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Authors:  Amy V Jones; Daniel Ward; Matthew Lyon; William Leung; Alison Callaway; Andrew Chase; Carolyn L Dent; Helen E White; Hans G Drexler; Jyoti Nangalia; Chris Mattocks; Nicholas C P Cross
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

4.  Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Authors:  Wendy T Parker; Stuart R Phillis; David T O Yeung; Timothy P Hughes; Hamish S Scott; Susan Branford
Journal:  Blood       Date:  2014-07-03       Impact factor: 22.113

5.  JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort.

Authors:  Gillian McGaffin; Kirsteen Harper; David Stirling; Lorna McLintock
Journal:  Br J Haematol       Date:  2014-06-17       Impact factor: 6.998

6.  Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Authors:  A Kohlmann; N Nadarajah; T Alpermann; V Grossmann; S Schindela; F Dicker; A Roller; W Kern; C Haferlach; S Schnittger; T Haferlach
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  Robustness of amplicon deep sequencing underlines its utility in clinical applications.

Authors:  Vera Grossmann; Andreas Roller; Hans-Ulrich Klein; Sandra Weissmann; Wolfgang Kern; Claudia Haferlach; Martin Dugas; Torsten Haferlach; Susanne Schnittger; Alexander Kohlmann
Journal:  J Mol Diagn       Date:  2013-05-14       Impact factor: 5.568

9.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

Authors:  Pontus Lundberg; Axel Karow; Ronny Nienhold; Renate Looser; Hui Hao-Shen; Ina Nissen; Sabine Girsberger; Thomas Lehmann; Jakob Passweg; Martin Stern; Christian Beisel; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more
  5 in total

1.  Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease.

Authors:  Anna Stengel; Sabine Jeromin; Torsten Haferlach; Manja Meggendorfer; Wolfgang Kern; Claudia Haferlach
Journal:  Haematologica       Date:  2018-11-08       Impact factor: 9.941

2.  The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Authors:  M O Holmström; C H Riley; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528

3.  A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations.

Authors:  Mi Ae Jang; Mi Yeon Seo; Kyoung Jin Choi; Dae Sik Hong
Journal:  J Korean Med Sci       Date:  2020-06-15       Impact factor: 2.153

Review 4.  Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.

Authors:  Lasse Kjær
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

Review 5.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.